All of the following are third generation antipsychotics except,

A. Repeated passage of saliva into clothing. There is no recognized disorder characterized by excessive saliva passage onto clothing. However, sialorrhea (excessive drooling) may occur in neurological conditions like cerebral palsy or as a side effect of medications like clozapine.

B. Repeated passage of feces into clothing. Encopresis is the repeated, involuntary or intentional passage of feces into inappropriate places, such as clothing or the floor, in children older than 4 years. It is often associated with chronic constipation, stool retention, and overflow incontinence, though it can also occur in response to emotional stress or behavioral issues.

C. Repeated passage of rights. This phrase does not correspond to any recognized medical or psychiatric condition.

D. Repeated voiding of urine into bed or clothing. This describes enuresis, not encopresis. Enuresis is the repeated involuntary or intentional voiding of urine into bed or clothing, occurring at least twice a week for three consecutive months in children older than 5 years. It can be nocturnal (night-time bedwetting), diurnal (daytime), or both.

A. Lurasidone (Latuda) is a second-generation (atypical) antipsychotic, not a third-generation antipsychotic. It primarily blocks dopamine (D2) and serotonin (5-HT2A) receptors and is used to treat schizophrenia and bipolar depression.

B. Cariprazine (Vraylar) is a third-generation antipsychotic, functioning as a partial dopamine (D2/D3) and serotonin (5-HT1A) receptor agonist. It is used for schizophrenia, bipolar disorder, and major depressive disorder (MDD) adjunctive treatment.

C. Haloperidol (Haldol) is a first-generation (typical) antipsychotic, not a third-generation antipsychotic. It works by strongly blocking D2 receptors, leading to a high risk of extrapyramidal symptoms (EPS) but lower metabolic side effects compared to atypical antipsychotics.

D. Aripiprazole (Abilify) is a third-generation antipsychotic, known for its partial dopamine (D2) agonist properties. It has a lower risk of EPS and metabolic side effects compared to second-generation antipsychotics and is used for schizophrenia, bipolar disorder, and adjunctive treatment in depression.